Early pharmacological interventions in youth

Dana Baker Kaplin, Ekaterina Stepanova, Bradley Grant, Dejan B. Budimirovic, Robert L Findling

Research output: Chapter in Book/Report/Conference proceedingChapter


Although well studied in adults, there is a relative dearth of clinical trials on the diagnosis and treatment of bipolar disorders (BD) in pediatric populations. The prevalence of bipolar spectrum disorders in youth is approximately 1.8% according to a metaanalysis conducted by Van Meter and colleagues. There is also growing evidence that BD may begin during pre-adolescence. Pediatric BD is a chronic illness and if untreated can be seriously debilitating. It is also a risk factor for suicide. Studies indicate that across bipolar disorders, earlier age of onset is associated with greater severity of illness and negative outcomes in adulthood. Pharmacologic interventions may be an effective treatment of BD in pediatric populations. Although there are currently several medications with FDA-approved indications for use in youth, given the chronic and harmful impact of BD, rigorous research that may lead to the delay of onset or progression of pediatric bipolarity is greatly needed.

Original languageEnglish (US)
Title of host publicationBipolar Disorder Vulnerability
Subtitle of host publicationPerspectives from Pediatric and High-Risk Populations
Number of pages18
ISBN (Electronic)9780128123478
ISBN (Print)9780128125601
StatePublished - Jan 1 2018


  • Clinical trials
  • Comorbidity
  • Depression
  • Mania
  • Pediatric bipolar disorder
  • Pharmacologic intervention
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)


Dive into the research topics of 'Early pharmacological interventions in youth'. Together they form a unique fingerprint.

Cite this